Altering the order of operations, using new resins, and increasing dynamic binding capacity can obviate the need for major facilty changes.
Brian Kelley
Advertisement
Brian Kelley is vice president, bioprocess development at Genentech, Inc.
Articles by Brian Kelley
Advertisement
Latest Updated Articles
Advertisement
Advertisement